Mark Breidenbach
Stock Analyst at Oppenheimer
(1.70)
# 3,239
Out of 4,944 analysts
56
Total ratings
32.2%
Success rate
0.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $10.57 | +183.82% | 4 | Sep 4, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $1.04 | +1,150.00% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $1.92 | +785.42% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $7.09 | +1,239.92% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $3.22 | +676.40% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.81 | +1,134.11% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $15.97 | +1,402.82% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $3.94 | +3,960.91% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.49 | +369.80% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.95 | +1,541.03% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $2.45 | +512.24% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.50 | +7,900.00% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.87 | +521,290.37% | 2 | May 12, 2020 |
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $10.57
Upside: +183.82%
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $1.04
Upside: +1,150.00%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $1.92
Upside: +785.42%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $7.09
Upside: +1,239.92%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $3.22
Upside: +676.40%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.81
Upside: +1,134.11%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $15.97
Upside: +1,402.82%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $3.94
Upside: +3,960.91%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.49
Upside: +369.80%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.95
Upside: +1,541.03%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $2.45
Upside: +512.24%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.50
Upside: +7,900.00%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.87
Upside: +521,290.37%